Next Article in Journal
RGD-Binding Integrins in Head and Neck Cancers
Next Article in Special Issue
Bridging Plant and Human Radiation Response and DNA Repair through an In Silico Approach
Previous Article in Journal
The Therapeutic Targeting of HGF/c-Met Signaling in Hepatocellular Carcinoma: Alternative Approaches
Previous Article in Special Issue
MTH1 as a Chemotherapeutic Target: The Elephant in the Room
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessReview
Cancers 2017, 9(6), 57;

Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma

Research Center, Policlinico di Monza Foundation, Via Pietro Micca 29, 13100 Vercelli, Italy
Author to whom correspondence should be addressed.
Academic Editor: Eddy S. Yang
Received: 10 March 2017 / Revised: 10 May 2017 / Accepted: 22 May 2017 / Published: 26 May 2017
(This article belongs to the Special Issue DNA Repair Pathways in Cancer)
Full-Text   |   PDF [2344 KB, uploaded 26 May 2017]   |  


Despite improvements in therapeutic strategies, glioblastoma (GB) remains one of the most lethal cancers. The presence of the blood–brain barrier, the infiltrative nature of the tumor and several resistance mechanisms account for the failure of current treatments. Distinct DNA repair pathways can neutralize the cytotoxicity of chemo- and radio-therapeutic agents, driving resistance and tumor relapse. It seems that a subpopulation of stem-like cells, indicated as glioma stem cells (GSCs), is responsible for tumor initiation, maintenance and recurrence and they appear to be more resistant owing to their enhanced DNA repair capacity. Recently, attention has been focused on the pivotal role of the DNA damage response (DDR) in tumorigenesis and in the modulation of therapeutic treatment effects. In this review, we try to summarize the knowledge concerning the main molecular mechanisms involved in the removal of genotoxic lesions caused by alkylating agents, emphasizing the role of GSCs. Beside their increased DNA repair capacity in comparison with non-stem tumor cells, GSCs show a constitutive checkpoint expression that enables them to survive to treatments in a quiescent, non-proliferative state. The targeted inhibition of checkpoint/repair factors of DDR can contribute to eradicate the GSC population and can have a great potential therapeutic impact aiming at sensitizing malignant gliomas to treatments, improving the overall survival of patients. View Full-Text
Keywords: glioblastoma; glioma stem cells; DNA damage/repair; chemoresistance glioblastoma; glioma stem cells; DNA damage/repair; chemoresistance

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Annovazzi, L.; Mellai, M.; Schiffer, D. Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma. Cancers 2017, 9, 57.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top